# üî¨ Etelcalcetide Path Analysis Report

*Generated: 2025-12-07 14:00:25*

## 1. Drug Profile

| Property | Value |
|----------|-------|
| **Drug ID** | DB12865 |
| **Drug Name** | Etelcalcetide |
| **Type** | drug |

## 2. Path Statistics

| Metric | Value |
|--------|-------|
| **Total Paths** | 100 |
| **Unique Diseases** | 57 |
| **Mean Attention** | 0.5223 |
| **Std Attention** | 0.0511 |
| **Min Attention** | 0.4672 |
| **Max Attention** | 0.7099 |

### Paths by Hop Count

| Hops | Count |
|------|-------|
| 1 | 2 |
| 2 | 62 |
| 3 | 70 |
| 4 | 400 |
| 5 | 400 |

## 3. Path Type Summary

| Path Type | Count | Description |
|-----------|-------|-------------|
| Drug Similarity | 0 | Paths through similar drugs |
| Protein Target | 98 | Paths through protein targets |
| Pathway | 0 | Paths through biological pathways |
| Biological Process | 0 | Paths through biological processes |
| Other | 2 | Other connection types |

## 4. Top 20 Paths (by Combined Score)

### Path #1: hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.467)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4672 |
| Combined Score | 0.4672 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Etelcalcetide may treat hyperparathyroidism based on embedding similarity.

---

### Path #2: hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.467)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 1 |
| Avg Attention | 0.4672 |
| Combined Score | 0.4672 |
| Confidence | ‚≠ê‚≠ê Low |

**Node Types:** `drug` ‚Üí `disease`

**Interpretation:**

**Direct prediction**: TxGNN predicts Etelcalcetide may treat hyperparathyroidism based on embedding similarity.

---

### Path #3: hereditary chronic pancreatitis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.550)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5143 |
| Combined Score | 0.3637 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in hereditary chronic pancreatitis. This represents a direct mechanistic link.

---

### Path #4: hereditary chronic pancreatitis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.550)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5143 |
| Combined Score | 0.3637 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in hereditary chronic pancreatitis. This represents a direct mechanistic link.

---

### Path #5: familial isolated hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.549)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5137 |
| Combined Score | 0.3632 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial isolated hyperparathyroidism. This represents a direct mechanistic link.

---

### Path #6: familial isolated hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.549)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5137 |
| Combined Score | 0.3632 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial isolated hyperparathyroidism. This represents a direct mechanistic link.

---

### Path #7: familial isolated hypoparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.544)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5112 |
| Combined Score | 0.3615 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial isolated hypoparathyroidism. This represents a direct mechanistic link.

---

### Path #8: familial isolated hypoparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.544)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5112 |
| Combined Score | 0.3615 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial isolated hypoparathyroidism. This represents a direct mechanistic link.

---

### Path #9: EIG1

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5060 |
| Combined Score | 0.3578 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in EIG1. This represents a direct mechanistic link.

---

### Path #10: EIG1

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.534)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5060 |
| Combined Score | 0.3578 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in EIG1. This represents a direct mechanistic link.

---

### Path #11: hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5026 |
| Combined Score | 0.3554 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in hyperparathyroidism. This represents a direct mechanistic link.

---

### Path #12: hyperparathyroidism

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5026 |
| Combined Score | 0.3554 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in hyperparathyroidism. This represents a direct mechanistic link.

---

### Path #13: familial hypocalciuric hypercalcemia

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5026 |
| Combined Score | 0.3554 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial hypocalciuric hypercalcemia. This represents a direct mechanistic link.

---

### Path #14: familial hypocalciuric hypercalcemia

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 2 |
| Avg Attention | 0.5026 |
| Combined Score | 0.3554 |
| Confidence | ‚≠ê‚≠ê‚≠ê Medium |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Target-based path**: Etelcalcetide targets CASR, which is implicated in familial hypocalciuric hypercalcemia. This represents a direct mechanistic link.

---

### Path #15: calcinosis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.531)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7099 |
| Combined Score | 0.3550 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to calcinosis through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

### Path #16: embryonal carcinoma

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.530)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7096 |
| Combined Score | 0.3548 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to embryonal carcinoma through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

### Path #17: pneumonitis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.529)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7095 |
| Combined Score | 0.3547 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to pneumonitis through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

### Path #18: nephrosis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.529)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7095 |
| Combined Score | 0.3547 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to nephrosis through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

### Path #19: familial tumoral calcinosis

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.527)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7089 |
| Combined Score | 0.3544 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to familial tumoral calcinosis through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

### Path #20: kidney disease

**Path:**
```
[Etelcalcetide] --(0.478)--> [CASR] --(0.874)--> [FLNA] --(0.956)--> [ITGB2] --(0.525)--> 
```

| Metric | Value |
|--------|-------|
| Hops | 4 |
| Avg Attention | 0.7085 |
| Combined Score | 0.3542 |
| Confidence | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High |

**Node Types:** `drug` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `gene/protein` ‚Üí `disease`

**Interpretation:**

**Multi-hop path**: Etelcalcetide connects to kidney disease through 3 intermediate nodes: CASR ‚Üí FLNA ‚Üí ITGB2. This represents a complex biological relationship requiring further validation.

---

## 5. Interpretation Guidelines

### Attention Score Scale

| Score Range | Confidence | Interpretation |
|-------------|------------|----------------|
| ‚â• 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê‚≠ê Very High | Strong biological relationship |
| 0.60 - 0.70 | ‚≠ê‚≠ê‚≠ê‚≠ê High | Good evidence for connection |
| 0.50 - 0.60 | ‚≠ê‚≠ê‚≠ê Medium | Moderate support |
| 0.40 - 0.50 | ‚≠ê‚≠ê Low | Weak connection |
| < 0.40 | ‚≠ê Very Low | Speculative |

### How to Use This Report

1. **Prioritize high-scoring paths**: Focus on paths with combined scores > 0.45
2. **Validate intermediate nodes**: Cross-reference proteins/drugs with literature
3. **Consider path length**: Shorter paths (2-3 hops) are generally more reliable
4. **Check for known associations**: Some paths may represent known indications

---

*Report generated by TxGNN Path Analysis Pipeline*